Live Breaking News & Updates on Prnewswire Auravax Therapeutics Inc

Stay updated with breaking news from Prnewswire auravax therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AuraVax Therapeutics Appoints Two Healthcare Veterans to its Board of Directors

/PRNewswire/ AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced. ....

United States , Laurence Cooper , Sanofi Pasteur , Joseph Sullivan , Thomas Finn , Merck Co Inc , Research Committee , American Academy Of Microbiology , Auravax Therapeutics Inc , Global Personal Health Care Pharmaceuticals , Icosavax Inc , International Society For Vaccines , Hamilton College , Procter Gamble Global Health Care , Rna Pharmaceuticals , Cincinnati Children Medical Center , Prnewswire Auravax Therapeutics Inc , Business Development , National Institutes Of Health , John Shiver Phd , Vax Therapeutics , John Shiver , Gamble Global Health Care , Global Personal Health Care , Global Pharmaceuticals , Global Strategic Planning ,

AuraVax Therapeutics recognizes its academic collaborator at the University of Houston for address at Keystone Conference

/PRNewswire/ AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced. ....

United States , University Of Houston , Navin Varadarajan , Ankita Leekha , Joseph Sullivan , Biomolecular Engineering At University Of Houston , Prnewswire Auravax Therapeutics Inc , Auravax Therapeutics Inc , Vax Therapeutics , Vaccinology During , Biomolecular Engineering , Chief Scientific Officer , Auravax Therapeutics ,

AuraVax Therapeutics Appoints Industry Veteran Joseph Sullivan as its Inaugural CEO

/PRNewswire/ AuraVax Therapeutics, Inc., a biotechnology company developing novel immunotherapies to prevent and treat respiratory viruses, today announced. ....

United States , Joe Sullivan , Auravax Theraputics , Josephc Sullivan , Matthewj Meyer , Laurence Cooper , Merck Co Inc , While At Nature Toolbox Inc , Auravax Therapeutics Inc , Prnewswire Auravax Therapeutics Inc , Vax Therapeutics , Chief Executive , Chief Commercial Officer , Auravax Therapeutics ,

AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform

AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform
Transaction supports development of AuraVax s lead COVID-19 intranasal program, plus other vaccines and therapeutics targeting respiratory diseases
News provided by
Share this article
Share this article
HOUSTON, Feb. 3, 2021 /PRNewswire/ AuraVax Therapeutics Inc. (www.auravax.com), a pioneering biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases including COVID-19, today announced it has entered into an exclusive license agreement with the University of Houston (UH) with respect to the intellectual property covering a novel intranasal vaccine and STING agonist technologies. This agreement converts the optioned intellectual property between UH and AuraVax announced on October 12, 2020. ....

University Of Houston , United States , Auravax Theraputics , Navin Varadarajan , Matthewj Meyer , Amr Elnashai , Phi Beta Kappa , Auravax Therapeutics Inc , Prnewswire Auravax Therapeutics Inc , Vax Therapeutics , Biomolecular Engineering , Carnegie Designated Tier One , Gulf Coast Region , Asian American Serving , பல்கலைக்கழகம் ஆஃப் ஹூஸ்டன் , ஒன்றுபட்டது மாநிலங்களில் , நவீன் வரதராஜன் , ஃபை பீட்டா கப்பா , வ்யாக்ஸ் சிகிச்சை , உயிர் மூலக்கூறு பொறியியல் , கார்னகி நியமிக்கப்பட்ட அடுக்கு ஒன்று , வளைகுடா கடற்கரை பகுதி , ஆசிய அமெரிக்கன் சேவை ,

AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform

AuraVax Therapeutics Enters into Exclusive License Agreement with Massachusetts General Hospital for Intranasal Vaccine and Therapeutics Platform
Transaction bolsters development of AuraVax s lead COVID-19 intranasal vaccine and strengthens platform for therapeutic development targeting a range of viral infections
News provided by
Share this article
Share this article
HOUSTON, Jan. 13, 2021 /PRNewswire/ AuraVax Therapeutics Inc. (www.auravax.com), a biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases, including COVID-19, today announced it has entered into an exclusive license agreement with Massachusetts General Hospital (MGH) covering certain intellectual property and technology rights regarding compositions and discoveries of liposomal STING agonists by Mei X. Wu, PhD, of the Wellman Center for Photomedicine at MGH. Research related to this technology was published in ....

University Of Houston , United States , Auravax Theraputics , Navin Varadarajan , Matthewj Meyer , Meix Wu , Auravax Therapeutics Inc , Prnewswire Auravax Therapeutics Inc , Wellman Center , Vax Therapeutics , Massachusetts General Hospital , Biomolecular Engineering , Health Care Amp Hospitals , Medical Pharmaceuticals , Clinical Trials Amp Medical Discoveries , பல்கலைக்கழகம் ஆஃப் ஹூஸ்டன் , ஒன்றுபட்டது மாநிலங்களில் , நவீன் வரதராஜன் , வெல்மேன் மையம் , வ்யாக்ஸ் சிகிச்சை , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை , உயிர் மூலக்கூறு பொறியியல் , ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் , மருத்துவ மருந்துகள் , உயிரி தொழில்நுட்பவியல் , மருத்துவ சோதனைகள் ஆம்ப் மருத்துவ கண்டுபிடிப்புகள் ,